BR112013019061A2 - composto inibidor da caspase-2, composição farmacêutica e uso de um composto - Google Patents
composto inibidor da caspase-2, composição farmacêutica e uso de um compostoInfo
- Publication number
- BR112013019061A2 BR112013019061A2 BR112013019061A BR112013019061A BR112013019061A2 BR 112013019061 A2 BR112013019061 A2 BR 112013019061A2 BR 112013019061 A BR112013019061 A BR 112013019061A BR 112013019061 A BR112013019061 A BR 112013019061A BR 112013019061 A2 BR112013019061 A2 BR 112013019061A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- caspase
- pharmaceutical composition
- inhibitor
- inhibitor compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22055—Caspase-2 (3.4.22.55)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152892 | 2011-02-01 | ||
| PCT/EP2012/051367 WO2012104224A1 (en) | 2011-02-01 | 2012-01-27 | Caspase-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013019061A2 true BR112013019061A2 (pt) | 2018-06-26 |
Family
ID=45688443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013019061A BR112013019061A2 (pt) | 2011-02-01 | 2012-01-27 | composto inibidor da caspase-2, composição farmacêutica e uso de um composto |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120196892A1 (pt) |
| EP (1) | EP2670774A1 (pt) |
| KR (1) | KR20140005215A (pt) |
| CN (1) | CN103339144A (pt) |
| AR (1) | AR085041A1 (pt) |
| BR (1) | BR112013019061A2 (pt) |
| CA (1) | CA2826200A1 (pt) |
| RU (1) | RU2013136045A (pt) |
| WO (1) | WO2012104224A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| CN109476631B (zh) | 2016-03-22 | 2021-04-06 | 国家健康与医学研究院 | 新衍生物及其作为胱天蛋白酶-2的选择性抑制剂的用途 |
| CN111741970A (zh) * | 2017-09-26 | 2020-10-02 | 法国国家科研中心 | 新型化合物及其作为胱天蛋白酶-2的选择性抑制剂的用途 |
| EP4112631A1 (en) | 2021-07-01 | 2023-01-04 | Kintsugi Therapeutics S.L. | Caspase-2 inhibitor compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060241034A1 (en) | 2003-05-22 | 2006-10-26 | David Chauvier | Means for preventing and treating cellular death and their biological applications |
| JP5053836B2 (ja) | 2004-04-30 | 2012-10-24 | テラプトシス エス アー | カスパーゼ−２阻害剤およびそれらの生物学的適用 |
| WO2006056487A2 (en) | 2004-11-24 | 2006-06-01 | Theraptosis S.A. | Peptides useful as dual caspase-2/-6 inhibitors and their biological applications |
| US20100184703A1 (en) * | 2007-06-27 | 2010-07-22 | Chiesi Farmaceutici S.P.A. | Use of peptide derivatives for treating pathologies resulting from ischemia |
-
2012
- 2012-01-27 CN CN2012800070770A patent/CN103339144A/zh active Pending
- 2012-01-27 EP EP12704726.4A patent/EP2670774A1/en not_active Withdrawn
- 2012-01-27 CA CA2826200A patent/CA2826200A1/en not_active Abandoned
- 2012-01-27 WO PCT/EP2012/051367 patent/WO2012104224A1/en active Application Filing
- 2012-01-27 KR KR1020137019588A patent/KR20140005215A/ko not_active Application Discontinuation
- 2012-01-27 BR BR112013019061A patent/BR112013019061A2/pt not_active IP Right Cessation
- 2012-01-27 RU RU2013136045/04A patent/RU2013136045A/ru not_active Application Discontinuation
- 2012-01-30 AR ARP120100298A patent/AR085041A1/es not_active Application Discontinuation
- 2012-01-31 US US13/362,104 patent/US20120196892A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2670774A1 (en) | 2013-12-11 |
| AR085041A1 (es) | 2013-08-07 |
| CN103339144A (zh) | 2013-10-02 |
| US20120196892A1 (en) | 2012-08-02 |
| WO2012104224A1 (en) | 2012-08-09 |
| KR20140005215A (ko) | 2014-01-14 |
| CA2826200A1 (en) | 2012-08-09 |
| RU2013136045A (ru) | 2015-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112015000420A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014029530A2 (pt) | compostos, composição farmacêutica e uso de um composto | |
| BR112014000260A2 (pt) | composto, e, uso de um composto | |
| BR112014001346A2 (pt) | composto nanotransportador, método, composto farmacêutico e uso de um composto | |
| BR112014029115A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| BR112014013177A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112013030302A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo | |
| BRPI1008793A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014003052A2 (pt) | composições farmacêuticas | |
| CO7020907A2 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| BR112014013178A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| CO6930367A2 (es) | Composiciones farmaceúticas | |
| BR112014016635A2 (pt) | composto, composição, e, uso de um composto | |
| BR112014009471A2 (pt) | compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| BR112014004310A2 (pt) | composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto | |
| BR112015002824A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2478 DE 03-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |